Primary screening for human papillomavirus infection

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 15, Issue 5, 2001, Pages 743-757

  Dillner, Joakim ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Aetiology orientated screening; Cancer prevention; Cervical cancer; Molecular epidemiology

Indexed keywords

CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; FEMALE GENITAL TRACT CYTOLOGY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; LONG TERM CARE; MASS SCREENING; META ANALYSIS; NONHUMAN; PAPANICOLAOU TEST; PATIENT SELECTION; POPULATION RISK; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SAFETY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS DETECTION; WART VIRUS;

EID: 0034751434     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2001.0217     Document Type: Article

References (68)

1. Epidemiological evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
2. Human papillomavirus infection is transient in young women: A population-based cohort study
3. Persistence of type-specific human papillomavirus infection among cytologically normal women
4. Natural history of cervicovaginal papillomavirus infection in young women
5. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
6. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
7. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears
8. Present evidence on the value of HPV-testing for cervical cancer screening. A model-based exploration of (cost)-effectiveness
9. Regional distribution and incidence of HPV infections among heterosexual men and women with multiple partners: A prospective study
10. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types
11. Human papillomavirus and cervical intraepithelial neoplasia grade II-III: A population-based case-control study
12. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types
13. A prospective cohort study on the risk to develop cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV, in comparison with presence of HPV DNA in cervical smears
14. A population-based study for predicting cervical intraepithelial neoplasia
15. A systematic review of the role of human papillomavirus testing within a cervical screening programme
16. The sexually transmitted disease model for cervical cancer: Incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection
17. Test reliability is critically important to molecular epidemiology: An example from studies of human papillomavirus infection and cervical neoplasia
18. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high risk and 6 low risk human papillomavirus types in cervical scrapings
19. Reliable high risk HPV DNA testing by polymerase chain reaction: An intermethod and intramethod comparison
20. Typing of human papillomaviruses by consensus polymerase chain reaction and a non-radioactive reverse dot blot hybridization
21. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica
22. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial
23. Additional human papillomavirus types detected by the hybrid capture tube test among samples from women with cytological and colposcopical atypia
24. PCR detection of human papillomavirus: Comparison between MY09/MY11 and GP5+/GP6+ primer systems
25. A population-based five-year follow-up study of cervical human papillomavirus infection
26. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies
27. Mass screening for cervical cancer in Östfold county of Norway 1959-1977
28. Pap smear screening and changes in cervical cancer mortality in Sweden
29. Strategies for global control of cervical cancer
30. Detection rates for abnormal cervical smears: What are we screening for?
31. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri
32. Breast cancer screening as public health policy in Finland
33. Commentary: Trials versus models in appraising screening programs
34. Withdrawing low risk women from cervical screening programmes: Mathematical modelling study
35. Setting the target for a better cervical screening test; Characteristics of a cost-effective test for cervical neoplasia screening
36. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia
37. Human papillomavirus in cell samples from the Stockholm gynecological health screening
38. Human papillomavirus testing in primary cervical screening
39. Population-based type-specific prevalence of high risk human papillomavirus infection in middle-aged Swedish women
40. HPV testing in primary screening of older women
41. The presence of persistent high risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months
42. Persistence of human papillomavirus infections preceding cervical carcinoma
43. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women
44. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study
45. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study
46. Prospective, seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer
47. Immune response against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV 16
48. The serological response to papillomaviruses
49. Immunity to oncogenic human papillomaviruses
50. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study
51. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer
52. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes
53. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer
54. A cohort study of cervical cancer screening in British Columbia
55. Type-specific persistence of human papillomavirus before invasive cervical cancer
56. Predicting mortality from cervical cancer after negative smear test results
57. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study
58. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri
59. Conization of CIN is followed by a disappearance of HPV DNA and a decline of serum and cervical mucus antibodies against HPV antigens
60. High risk HPV persists after treatment of genital papillomavirus infection, but not after treatment for cervical intraepithelial neoplasia
61. Human papillomavirus DNA after treatment of cervical dysplasia: Low prevalence in normal cytologic smears
62. Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia
63. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser
64. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia
65. Can papillomavirus testing be used to improve cervical cancer screening?